## Supplementary Table S1: Study Design

| | Study Design/Properties | | | | | | No of patients | Epidimiological data | | Follow up | | Assessment | | Study Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Study | Year | Country | Study Design | | | | mean age | BMI (kg/m2) | time (months) | loss to follow up (12 months) | Modality | point of time (months) | NIH Rating |
| Lin XL, 2020 | Comparison between microwave ablation and radiofrequency ablation for treating symptomatic uterine adenomyosis | 10/2015 - 10/2017 | China | Experimental (II) | single-center, randomized, parallel and controlled clinical trial | prospective | 65 | 38.9 ± 5.0 | 22.0 ± 3.3 | 12 | none | post ablation CEUS and cMRI at day3, SSS and VRS Scores thereafter inlcuding TVUS. | (day 3 MRI) 3,12 | good |
| Nam JH., 2020 | Pregnancy and symptomatic relief following ultrasound-guided transvaginal radiofrequency ablation in patients with adenomyosis | 08/2004 - 11/2014 | South Korea | descriptive (VI) | case series | retrospective | 81 | 35.6 (26–44) | n/a | 57.4 (3-129) | 33.8% (26) on outcome symptoms. 5% (4) on outcome pregnancy | PBAC and PAIN Score | 1,3,6,12,24,36,48 | fair |
| Hai N, 2017 | Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis | 2013 - 10/2015 | China | descriptive (VI) | case series | retrospective | 81 | 40.0 ± 8.5 | 22.5 ± 2.4 | 12 | 6.9% (6/87) | post ablation CEUS (= NPV 70%) and then TVUS thereafter. VAS | 1,6,12 | good |
| Hai N, 2021 | Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment | 01/2013 - 01/2016 | China | descriptive (VI) | case series | retrospective | 64 | 39.2 ± 4.9 | 22.5 ± 2.9 | 12 | 12.3% (9/73) | post ablation CEUS (= NPV 70%) and then TVUS thereafter. Blood sampels at 3,6 months, VAS | 3, 6,12, 24, 36 | good |
| Scarperi S, 2015 | Laparoscopic Radiofrequency Thermal Ablation for Uterine Adenomyosis | n/a | Italy | descriptive (VI) | case series | prospective | 15 | 40.1 (34–46) | 23.9 | 9 (3-12) | 33% (5) | Ultrasound/VAS | 3, 6, 9, 12 | fair |
| Stepniewska AK, 2022 | Heat can treat: long-term follow-up results after uterine-sparing treatment of adenomyosis with radiofrequency thermal ablation in 60 hysterectomy candidate patients | 03/2011 - 06/2019 | Italy | observational (III) | cohort study | retrospective | 60 | 43 (38–50) ± 3.0 | n/a | 56 (10–115, ± 29) | none | Ultrasound/Scores | not specified | good |
| Sha A Dai Ti WFE, 2018 | Clinical evaluation of three methods in the treatment of adenomyosis | 01/2013 - 01/2016 | China | observational (III) | cohort study | retrospective | 30 | 37.33 ± 4.25 | n/a | 12 | n/a | n/a | n/a | poor |
| | **Weighted Mean** | | | | | | | **39.0** | **22.4** | **27.8** | **12.5%** | | | |
| | **Weighted SD ±** | | | | | | | 2.3 | 0.4 | 21.6 | 13.4% | | | |